
RLY-2608 Plus Fulvestrant Demonstrates Efficacy in PIK3CA-Mutated, HR+/HER2– Advanced Breast Cancer
RLY-2608 in combination with fulvestrant (Faslodex) displayed a tolerable safety profile and preliminary activity in patients with PIK3CA-mutated, hormone receptor (HR)–positive, HER2-negative advanced breast cancer, paving the way for the combination to …